Factors Influencing Glycemic Control Response of Sitagliptin.
10.4093/jkd.2013.14.4.206
- Author:
Gun Woo KIM
1
;
Jae Hyun KIM
;
Mi Young LEE
;
Jang Yel SHIN
;
Young Goo SHIN
;
Eun Ho HA
;
Choon Hee CHUNG
Author Information
1. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. cchung@yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Dipeptidyl-peptidase IV inhibitors;
Sitagliptin;
Type 2 diabetes mellitus
- MeSH:
Adipose Tissue;
Biomarkers;
Blood Glucose;
Diabetes Mellitus, Type 2;
Dipeptidyl Peptidase 4;
Dipeptidyl-Peptidase IV Inhibitors;
Female;
Glucose;
Humans;
Incretins;
Kangwon-do;
Logistic Models;
Male;
Retrospective Studies;
Sitagliptin Phosphate
- From:Journal of Korean Diabetes
2013;14(4):206-211
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to reduce blood glucose in type 2 diabetes by prolonging the activity of circulating incretins. However, the factors that affect the efficacy of sitagliptin have not yet been demonstrated. Therefore, we studied them in a Korean population. METHODS: We performed a retrospective analysis in patients taking sitagliptin in Wonju Christian Hospital. One hundred-fifty patients whose serum HbA1c ranged from 6.5% to 11% participated in this study. These patients were divided into two groups: responder and non-responder. The responder group consisted of subjects with glucose lowering greater than 5% of baseline HbA1c. The others were in non-responder group. We analyzed anthropometric data and biochemical markers in all groups, then compared responder group and non-responder group by logistic regression. RESULTS: The change in HbA1c level across all groups was 8.25 +/- 0.82% to 7.64 +/- 1.03% (P value = 0.000). There were 93 and 57 patients in responder and non-responder group, respectively. The responder group had lower BMI, body fat (kg), body fat (%) than the non-responder group (P value = 0.024, P value = 0.029, P value = 0.025), and the HbA1c lowering effect of sitagliptin was greater in male than female (P value = 0.000). CONCLUSION: In this study, HbA1c was effectively lowered in 62% of the patients. The factors that affect the efficacy of sitagliptin were BMI, body fat (kg) body fat (%), and sex. Based on these results, we conclude that sitagliptin lowers glucose more effectively in non-obese male patients.
